^aDepartment of Chemistry, Faculty of Arts and Sciences, Bozok University, Yozgat, Turkey ^bDepartment of Chemistry, Faculty of Arts and Sciences, Anadolu University, Eskişehir, Turkey *E-mail: hungoren@yahoo.com

Received April 12, 2011

DOI 10.1002/jhet.1509

Published online 31 October 2013 in Wiley Online Library (wileyonlinelibrary.com).



Furan-3-one derivatives **1** were converted into 2-hydroxy-pyrrole-3-ones **4** by reacting with various α - and β -amino acids. In contrast, the reaction of furan-3-ones and 1-aminocyclobutanecarboxylic acid afforded spiro-pyrrolo[2,1-*b*][1,3]oxazoles **5** via the pyrrole-3-one intermediate under the same reaction conditions. Some of 2-hydroxy-pyrrole-3-ones **3** derived from anthranilic acids were transformed to pyrrolo[1,2-*a*][3,1] benzoxazines via intramolecular esterification.

J. Heterocyclic Chem., 51, 212 (2014).

INTRODUCTION

Amino acids play crucial roles both as building blocks of proteins and as intermediates in metabolism. Moreover, some natural heterocycles and synthetic drugs contained cyclic amino acid units for instance guanin, caffeine, lukianol A, diazepam, URB754, and cetilistat. Therefore, naturally occurring or synthetically obtained heterocyclic amino acid derivatives constitute an important resource for new drugs [1–4]. Especially, synthesis of novel heterocyclic systems provides new contributions to these research topics.



Pyrroles and their condensed compounds become increasingly important in medicinal chemistry and organic synthesis [5]. For instance, lamellarins, lukianols [6], and terresoxazine [7], which possess a pyrrole ring, are natural and bioactive products that were isolated from marine organism or plant. In the light of this, pyrroles including amino acid units are interesting compounds from the viewpoint of both their synthesis and biological applications.

In the course of our recent studies on the furan chemistry, it was shown that pyrroles including amino acid moiety could be prepared from the reactions of amino acids with 2-methylene-furan-3-ones [8]. In this work, we aimed to prepare novel pyrroles, spiro-pyrrolo-oxazoles and pyrrolobenzoxazoles, as new amino acid heterocycles on the basis of 2-methylene-furan-3-one chemistry.

RESULTS AND DISCUSSIONS

Various anthranilic acid derivatives 2 reacted with 2-methylene-furan-3-ones 1 in methanol in the presence of pyridine to give the corresponding 2,3-dihydro-1*H*-pyrrol-3-ones (3) as described in Scheme 1. Although the compounds 3 have an alcohol group and an acid group at corresponding positions of the molecule, these groups did not react to give pyrrolo[1,2-a][3,1]benzoxazin-5-one by intramolecular esterification, spontaneously.



Scheme 1. Reaction of furan-3(2H)-ones with anthranilic acid derivatives.



Compounds 1 also led to the corresponding pyrrole-3one skeleton 4 by reacting β -alanine and 1-aminocyclopropanecarboxylic acid (Scheme 2). On the other hand, spiro-pyrrolo[2,1-*b*][1,3]oxazoles 5 were obtained from the reaction of 1 with 1-aminocyclobutanecarboxylic acid via the pyrrole-3-one intermediate. In the ¹H NMR spectra, the methylene protons attached to an asymmetric center of a pyrrole ring show the signals of AB system as four lines. The signals of these diastereotopic protons clearly revealed the proposed pyrrole structure.

The structure of compound **5a** was determined from X-ray crystallography method [9]. The molecular structure of **5a** with the atom labeling is shown Figure 1. There are five ring systems, which are cyclobutane [Cg1: C(6)-C(7)-C(8)-C(9)], oxazole [Cg2: N(1)-C(4)-O(2)-C(8)

Scheme 2. Reaction of furan-3(2H)-ones with aliphatic amino acids.



able at www.interscience.wiley.com.]

for clarity). [Color figure can be viewed in the online issue, which is avail-

(5)–C(6)], pyrrole [Cg3: N(1)–C(2)–C(3)–C(4)], and two phenyl rings [Cg4: C(10)–C(11)–C(12)–C(13)–C(14)–C (15); Cg5: C(18)–C(19)–C(20)–C(21)–C(22)–C(23)] in molecular structure. C–C bond distances ranging from 1.518(3) Å [C(7)–C(8)] to 1.549(3) Å [C(6)–C(9)] and average bond angle value is 89.94° in cyclobutane ring. The bond distances are typical single-bond character in oxazole ring. The dihedral angles of the N(1)–C(4)–O (2)–C(5)–C(6) oxazole plane with the C(6)–C(7)–C(8)–C (9) cyclobutane plane and the N(1)–C(2)–C(3)–C(4) pyrrole plane are 87.21° and 48.73°, respectively.

The crystal packing of **5a** is a composite of C–H··· π and C=O··· π interactions. Inter molecular C–H··· π interaction occurs between C(25)–H(25B) and Cg(4). The H-ring centroid (H···Cg) distance is 2.65 Å, and the γ angle is 2.83°. C(25)–H(25B)···Cg4 angles, 142°, is below the optimal value (180°) for the strongest C–H··· π interaction, which may be due to the steric constraints in the molecule. In addition, there is also C=O··· π interaction between C(5)–O(3) group and pyrrole ring center [C(5)–O(3)···Cg (3)=3.838 Å].

The reactions of **3** with SOCl₂ in benzen at 50 °C are composed of complex crude products. According to the NMR data, the crude products contain both intramolecular esterification products and also β -elimination products as by-product. The compounds **6a,l** could be isolated from some crude products by using column chromatography method (Scheme 3).

The reaction products of **3a,l** with SOCl₂ do not show the absorptions of –OH groups. This observation is clearly revealed to intramolecular esterification of **3a,l**. In addition to this, intramolecular esterifications of **3a,l** were verified



Scheme 3. Products from the reaction of some 2,3-dihydro-1*H*-pyrrol-3-ones attached to anthranilic acids with SOCl₂.

by the detection of lacton C=O absorbtion of **6a,l**. The spectroscopic data of all synthesized compounds are in agreement with the proposed structure.

CONCLUSIONS

We have synthesized novel 2,3-dihydro-1*H*-pyrrol-3-one, pyrrolo[1,2-*a*][3,1]benzoxazin-5-one, and pyrrolo[2,1-*b*][1,3] oxazole compounds containing amino acid units in miscellaneous yields from 2-methylene-furan-3-ones. This report is the first about synthesis and crystal structure of a spiro-pyrrolo[2,1-*b*][1,3]oxazole ring system. These functiona-lized products with amino acid units are amenable to further transformations, and we anticipate that they may have important applications in medicinal and synthetic organic chemistry.

EXPERIMENTAL

The starting materials **1a,b** were prepared according to Saçmacı [8] and Üngören [10]. Melting points were determined on an Electrothermal 9200 apparatus and are uncorrected. We carried out elemental analyses (C, H, N) using LECO-932 CHNS-O analyzer. We recorded IR spectra on a Jasko Plus Model 460 FT-IR Spectrometer as KBr pellets and Perkin Elmer Spectrum 400 FT-IR Spectrometer by using the ATR method. We obtained ¹H (300.13 MHz) and ¹³C (75.47 MHz) NMR by using Bruker Ultrashield in CDCl₃ and DMSO-*d*₆. All experiments were followed by tlc using DC Alufolien Kieselgel 60F 254 Merck and Camag TLC lamb (254/366 nm).

Crystallographic analyses: We collected diffraction data for complexes with a Bruker AXS APEX [11] CCD diffractometer equipped with a rotation anode at 100 (2)K by using graphite monochrometed Mo K α radiation ($\lambda = 0.71069$ Å). Diffraction data were collected over the full sphere and were corrected for absorption. The data reduction was performed with the SAINT program package. We found the structure solution with the SHELXS-97 [12] package by using the direct methods, and we refined SHELXL-97 [13] against F² by using first isotropic. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were added to the structure model at calculated positions. Geometric calculations were performed with Platon [14]. We obtained molecular drawings by using mercury [15].

General procedure for the preparation of 2,3-dihydro-1*H*pyrrol-3-one (3, 4) and pyrrolo[2,1-b][1,3]oxazol (5) from the α - and β -amino acid derivatives. Corresponding α - and β amino acid derivatives (1 mmol) and 1a,b (1 mmol) were refluxed in a mixture of 50 mL methanol and about 1 mL of pyridine for 1 h. To the crude product was added 30 mL 1 *M* HCl solution. The mixture was extracted with AcOEt (3 × 20 mL), and the solvent was removed by evaporation. The combined organic extracts were dried (MgSO₄). The solvent was removed on a rotary evaporator, and the residue was subjected to column chromatography on Silica gel 60 *HF*₂₅₄. Elution with AcOEt afforded the product.

2-[2-Hydroxy-4-(4-methoxybenzoyl)-2-(2-methoxy-2-oxoethyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]benzoic This compound was obtained as pale yellow crystals, acid (3a). 0.351 g (66%), mp 132 °C; ir (KBr): 3429 (OH, acid), 3251 (OH, alcohol), 1736, 1691, 1628, 1605 (C=O), 1576 cm⁻¹ ¹ (C=C); ¹H NMR (300 MHz, CDCl₃): δ 7.90–6.50 (m, 12H, Ar–H), 3.76, 3.74, 3.59 (3s, 9H, 3 MeO), 3.36 (A part of AB system, d, 1H, J = 15.4, CH₂COOMe), 3.00 (B part of AB system, d, 1H, J = 15.4, CH₂COOMe); ¹³C NMR (75 MHz, CDCl₃): δ 195.2, 189.7, 178.7, 170.3 (4C=O), 162.9, 161.4, 145.0, 136.3, 133.1, 132.5, 132.0, 131.8, 131.4, 131.0, 128.7, 121.1, 1113.6, 113.1, 112.8 (Ar-C=C, C=C), 91.0 (N-C-OH), 55.3, 55.1, 52.2 (3 MeO), 40.5 (CH₂). Anal. Calcd for C₂₉H₂₅NO₉ (531.5 g/mol): C, 65.53; H, 4.74; N, 2.64. Found: C, 65.18; H, 4.52; N 3.01.

5-Hydroxy-2-[2-hydroxy-4-(4-methoxybenzoyl)-2-(2-methoxy-2oxoethyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1yl]benzoic acid (3b). This compound was obtained as pale green crystals, 0.223 g (41%), mp 167 °C; ir (KBr): 3393 (OH, acid), 3247 (OH, alcohol), 1730, 1692 (C=O), 1577 cm⁻¹ (C=C); ¹H NMR (300 MHz, DMSO- d_6): δ 10.07 (s, 1H, Ar-OH), 7.88-6.72 (m, 11H, Ar-H), 3.83, 3.68, 3.62 (3s, 9H, 3 MeO), 3.46 (s, 1H, COOH, br), 2.95 (A part of AB system, d, 1H, J=15.4, CH₂COOMe), 2.69 (B part of AB system, d, 1H, J = 15.4, CH₂COOMe); ¹³C NMR (75 MHz, DMSO-d₆): δ 194.0, 188.5, 178.6, 169.1 (4 C=O), 168.5, 162.9, 161.0, 160.9, 157.4, 132.3, 132.1, 132.0, 131.6, 131.2, 126.4, 122.5, 119.1, 117.5, 113.7, 113.6 (Ar-C=C, C=C), 90.2 (N-C-OH), 55.9, 55.6, 52.3 (3 MeO), 41.0 (CH₂). Anal. Calcd for C₂₉H₂₅NO₁₀ (548.5 g/mol): C, 63.62; H, 4.60; N, 2.56. Found: C, 63.84; H, 4.51; N 2.31.

2-[2-Hydroxy-4-(4-methoxybenzoyl)-2-(2-methoxy-2-oxoethyl)-5-(4-methoxybenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]-5-methylbenzoic acid (3c). This compound was obtained as pale yellow crystals, 0.454 g (83%), mp 129 °C; ir (KBr): 3423 (OH, acid), 3224 (OH, alcohol), 1737, 1690, 1631, 1605 (C=O), 1575 cm⁻¹ (C=C); ¹H NMR (300 MHz, CDCl₃): δ 7.71–6.49 (m, 11H, Ar–H), 3.74, 3.72, 3.57 (3s, 9H, 3 MeO), 3.33 (A part of AB system, d, 1H, J=15.4, CH₂COOMe), 2.96 (B part of AB system, d, 1H, J=15.4, CH₂COOMe), 2.29 (s, 3H, Me); ¹³C NMR (75 MHz, CDCl₃): δ 195.3, 189.7, 179.0, 170.7 (4 C=O), 162.8, 161.3, 144.8, 138.9, 133.3, 133.0, 132.3, 132.0, 131.5, 131.3, 130.7, 121.3, 113.6, 113.1, 112.7 (Ar-C=C, C=C), 90.9 (N-C-OH), 55.3, 55.1, 52.2 (3 MeO), 40.5 (CH₂), 21.0 (Me). *Anal.* Calcd for C₃₀H₂₇NO₉ (545.5 g/mol): C, 66.05: H, 4.99; N, 2.57. Found: C, 66.35; H, 4.95; N, 2.90.

2-[2-Hydroxy-4-(4-methoxybenzoyl)-2-(2-methoxy-2-oxoethyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]-3,5-This compound was obtained as dimethylbenzoic acid (3d). pale yellow crystals, 0.245 g (44%), mp 136°C; ir (KBr): 3437 (OH, acid), 3282 (OH, alcohol), 1804, 1742, 1706, 1647, 1600 (C=O), 1574 cm^{-1} (C=C); ¹H NMR (300 MHz, DMSO- d_6): δ 8.64–6.47 (m, 10H, Ar–H), 3.82, 3.67, 3.58 (3s, 9H, 3 MeO), 3.34 (s, 1H, COOH, br), 2.86 (A part of AB system, d, 1H, J=15.4, CH₂COOMe), 2.63 (B part of AB system, d, 1H, J=15.4, CH₂COOMe), 2.27, 2.01 (2s, 6H, 2 Me); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 194.9, 188.6, 179.0, 169.7 (4 C=O), 162.9, 161.1, 138.5, 138.2, 134.7, 132.4, 132.0, 131.0, 130.6, 129.3, 129.3, 122.9, 113.6, 113.6, 111.6 (Ar-C=C, C=C), 90.7 (N-C-OH), 55.9, 55.6, 52.1 (3 MeO), 40.0 (CH₂) 20.8, 18.1 (2 Me). Anal. Calcd for C31H29NO9 (559 g/mol): C, 66.54; H, 5.22; N, 2.50. Found: C, 66.15; H, 5.19; N, 2.53.

2-[2-Hydroxy-4-(4-methoxybenzoyl)-2-(2-methoxy-2-oxoethyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]-5methoxybenzoic acid (3e). This compound was obtained as pale yellow crystals, 0.433 g (77%), mp 105 °C; ir (KBr): 3451 (OH, acid), 3217 (OH, alcohol), 1737, 1688, 1631, 1604 (C=O), 1573 cm⁻¹ (C=C); ¹H NMR (300 MHz, CDCl₃): δ 7.81 (br, 2H, 2 OH,), 7.76-6.49 (m, 11H, Ar-H), 3.76, 3.75, 3.72, 3.59 (4s, 12H, 4 MeO), 3.32 (A part of AB system, d, 1H, J=15.4, CH₂COOMe), 2.96 (B part of AB system, d, 1H, J=15.4, CH₂COOMe); ¹³C NMR (75 MHz, CDCl₃): δ 195.2, 189.6, 179.0, 170.4 (4C=O), 162.8, 161.3, 159.1, 134.5, 132.1, 132.0, 131.4, 131.3, 128.7, 128.3, 121.3, 118.3, 116.0, 113.6, 113.1 (Ar-C=C, C=C), 90.8 (N-C-OH), 55.6, 55.3, 55.1, 52.2 (4 MeO), 40.4 (CH₂). Anal. Calcd for C₃₀H₂₇NO₁₀ (561 g/mol): C, 64.17; H, 4.85; N, 2.49. Found: C, 64.22; H, 5.00; N, 2.20.

2-[2-Hydroxy-4-(4-methoxybenzoyl)-2-(2-methoxy-2-oxoethyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]-4,5dimethoxybenzoic acid (3f). This compound was obtained as pale yellow crystals, 0.162 g (27%), mp 107 °C; ir (KBr): 3446-3352 (OH, acid), 3135 (OH, alcohol), 1735, 1688, 1627, 1603 (C=O), 1574 cm⁻¹ (C=C); ¹H NMR (300 MHz, CDCl₃): δ 7.74-6.22 (m, 10H, Ar-H), 4.00, 3.87, 3.83, 3.77, 3.74 (5s, 15H, 5 MeO), 3.37 (A part of AB system, d, 1H, J=15.4, CH₂COOMe), 3.00 (B part of AB system, d, 1H, J=15.4, CH_2COOMe); ¹³C NMR (75 MHz, CDCl₃): δ 194.8, 189.5, 178.8, 169.9 (4C=O), 162.9, 161.4, 152.3, 144.5, 131.9, 131.3, 130.9, 130.3, 128.7, 124.4, 113.7, 113.7, 113.5, 113.1, 112.7 (Ar-C=C, C=C), 90.9 (N-C-OH), 56.4, 56.1, 55.3, 55.1, 52.3 (5 MeO), 41.0 (CH₂). Anal. Calcd for C₃₁H₂₉NO₁₁ (591 g/mol): C, 62.94; H, 4.94; N, 2.37. Found: C, 62.88; H, 5.24; N, 2.52.

5-Bromo-2-[2-hydroxy-4-(4-methoxybenzoyl)-2-(2-methoxy-2oxoethyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-*I-yl]benzoic acid (3g).* This compound was obtained as pale yellow crystals, 0.452 g (74%), mp 146 °C; ir (KBr): 3452 (OH, acid), 3394 (OH, alcohol), 1736, 1704, 1608 (C=O), 1575 cm⁻¹ (C=C); ¹H NMR (300 MHz, CDCl₃): δ 9.66 (OH, br), 7.84–6.51 (m, 11H, Ar–H), 3.77, 3.73, 3.62 (3s, 9H, 3 MeO), 3.35 (A part of AB system, d, 1H, *J*=15.4, CH₂COOMe), 3.00 (B part of AB system, d, 1H, *J*=15.4, CH₂COOMe); ¹³C NMR (75 MHz, CDCl₃): δ 195.1, 189.4, 178.3, 170.1 (4C=O), 162.9, 161.4, 145.6, 136.9, 135.2, 134.8, 134.4, 132.5, 131.9, 131.3, 122.4, 121.1, 113.7, 113.4, 113.1 (Ar-C=C, C=C), 90.9 (N-C-OH), 55.3, 55.1, 52.2 (3 MeO), 40.7 (CH₂). *Anal.* Calcd for $C_{29}H_{24}BrNO_9$ (610 g/mol): C, 57.06; H, 3.96; N, 2.29. Found: C, 57.22; H, 4.25; N, 2.26.

5-Chloro-2-[2-hydroxy-4-(4-methoxybenzoyl)-2-(2-methoxy-2oxoethyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1yl]benzoic acid (3h). This compound was obtained as pale yellow crystals, 0.368 g (65%), mp 127 °C; ir (KBr): 3428 (OH, acid), 3234 (OH, alcohol), 1736, 1692, 1633, 1604 (C=O), 1575 cm^{-1} (C=C); ¹H NMR (300 MHz, CDCl₃): δ 8.47 (OH, br), 7.73-6.51 (m, 11H, Ar-H), 3.75, 3.72, 3.60 (3s, 9H, 3 MeO), 3.34 (A part of AB system, d, 1H, J=15.4, CH₂COOMe), 2.95 (B part of AB system, d, 1H, J = 15.4, CH₂COOMe); ¹³C NMR (75 MHz, CDCl₃): δ 195.2, 189.6, 178.5, 169.6 (4 C=O), 162.9, 161.5, 144.2, 135.9, 134.6, 134.5, 132.2, 132.0, 131.7, 131.3, 131.2, 126.2, 121.0, 113.7, 113.1 (Ar-C=C, C=C), 91.0 (N-C-OH), 55.3, 55.1, 52.2 (3 MeO), 40.6 (CH₂). Anal. Calcd for C₂₉H₂₄ClNO₉ (566 g/mol): C, 61.54; H, 4.27; N, 2.47. Found: C, 61.24; H, 4.16; N, 2.36.

2-[2-(2-Ethoxy-2-oxoethyl)-2-hydroxy-4-(4-methoxybenzoyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]benzoic acid (3i). This compound was obtained as pale yellow crystals, 0.197 g (36%), mp 111 °C; ir (KBr): 3429 (OH, acid), 3378 (OH, alcohol), 1732, 1691, 1631, 1602 (C=O), 1575 (C=C). ¹H NMR (300 MHz, CDCl₃): 7.79–6.51 (m, 12H, Ar–H), 4.21 (q, ³J=6.9, 2H, OCH₂), 3.77, 3.60 (2s, 6H, 2 MeO), 3.35 (A part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.98 (B part of AB system, d, 1H, J=15.4, CH₂COOEt), 1.25 (t, ³J=6.9, Me); ¹³C NMR (75 MHz, CDCl₃): δ 195.1, 189.6, 178.9, 170.7 (4C=O), 162.9, 161.3, 144.5, 136.2, 133.6, 132.4, 132.0, 131.5, 131.3, 131.0, 128.6, 121.1, 113.58, 113.6, 113.1, 112.9 (Ar–C=C, C=C), 91.0 (N–C–OH), 61.2 (OCH₂CH₃), 55.3, 55.1 (2 MeO), 40.8 (C–CH₂COEt), 14.1 (OCH₂CH₃). Anal. Calcd for: C₃₀H₂₇NO₉ (545 g/mol): C, 66.05; H, 4.99; N, 2.57. Found: C, 65.97; H, 5.14; N, 2.84.

2-[2-(2-Ethoxy-2-oxoethyl)-2-hydroxy-4-(4-methoxybenzoyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]-5hydroxybenzoic acid (3j). This compound was obtained as pale green crystals, 0.320 g (57%), mp 155 °C; ir (KBr): 3380 (OH, acid), 3208 (OH, alcohol), 1729, 1692, 1604 (C=O), 1573 cm^{-1} (C=C); ¹H NMR (300 MHz, DMSO- d_6): δ 7.97–6.61 (m, 11H, Ar–H), 4.09 (q, ${}^{3}J$ =7.1, 2H, OCH₂), 3.83, 3.68 (2s, 6H, 2 MeO), 3.40 (OH, alcohol, br), 2.94 (A part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.68 (B part of AB system, d, 1H, J=15.4, CH₂COOEt), 1.15 (t, ${}^{3}J=7.1$, 3H, Me); ^{13}C NMR (75 MHz, DMSO-*d*₆): δ 194.0, 188.5, 178.7, 168.6 (4 C=O), 163.0, 161.0, 157.4, 132.9, 132.4, 132.0, 131.3, 129.2, 122. 5, 119.2, 118,2, 117.6, 115.7, 113.7, 113.6 (Ar-C=C, C=C), 90.3 (N-C-OH), 61.1 (OCH₂CH₃), 55.9, 55.6 (2 MeO), 41.4 (C-CH₂COEt), 14.4 (OCH₂CH₃). Anal. Calcd for C₃₀H₂₇NO₁₀ (561 g/mol): C, 64.17; H, 4.85; N, 2.49. Found: C, 64.22; H, 5.00; N, 2.20.

2-[2-(2-Ethoxy-2-oxoethyl)-2-hydroxy-4-(4-methoxybenzoyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]-5methylbenzoic acid (3k). This compound was obtained as pale yellow crystals 0.419 g (75%), mp 135°C; ir (KBr): 3428 (OH, acid), 3378 (OH, alcohol), 1732, 1690, 1631, 1605 (C=O), 1575 cm⁻¹ (C=C); ¹H NMR (300 MHz, DMSO- d_6): δ 7.80–6.71 (m, 11H, Ar–H), 4.09 (q, ³J=7.1, 2H, OCH₂), 3.83, 3.67 (2s, 6H, 2 MeO), 2.97 (A part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.31 (s, 3H, Me), 1.15 (t, ³J=7.1, 3H, Me); ¹³C NMR (75 MHz, DMSO- d_6): δ 193.9, 188.5, 178.3, 168.6 (4 C=O), 163.0, 161.1, 149.9, 138.6, 133.2, 133.2, 132.3, 132.0, 131.7, 131.3, 129.2, 122.3, 113.9, 113.6, 112.2 (Ar-C=C, C=C), 90.4 (N-C-OH), 61.1 (OCH₂CH₃), 55.9, 55.6 (2 MeO), 41.5 (C-CH₂CO₂Et), 20.9 (Ar-CH₃), 14.4 (OCH₂CH₃). Anal. Calcd for C₃₁H₂₉NO₉ (559 g/mol): C, 66.54; H, 5.22; N, 2.50. Found: C, 66.15; H, 5.19; N, 2.53.

2-[2-(2-Ethoxy-2-oxoethyl)-2-hydroxy-4-(4-methoxybenzoyl)-5-(4-methoxy phenyl) - 3 - oxo - 2, 3 - dihydro - 1H - pyrrol - 1 - yl] - 3, 5 - ychow and a start of the second start of thedimethylbenzoic acid (31). This compound was obtained as pale yellow crystals, 0.253 g (44%), mp 120°C; ir (KBr): 3425 (OH, acid), 3240 (OH, alcohol), 1734, 1691, 1631, 1604 (C=O), 1575 cm^{-1} (C=C). ¹H NMR (300 MHz, DMSO- d_6): δ 7.82–6.73 (m, 10H, Ar–H), 4.04 (q, ${}^{3}J=7.1$, 2H, –OCH₂), 3.82, 3.66 (2s, 6H, 2 MeO), 2.63 (A part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.17 (B part of AB system, d, 1H, J=15.4, CH_2 COOEt), 2.27 (2s, 6H, 2 Me), 1.16 (*t*, 3J =7.1, 3H, Me); ¹³ \overline{C} NMR (75 MHz, DMSO-*d*₆): δ 194.7, 188.6, 179.2, 169.7 (4C=O), 162.9, 161.2, 138.8, 138.4, 136.9, 132.4, 132.0, 131.0, 130.7, 129.5, 129.2, 122.8, 113.7, 113.6, 111.6 (Ar-C=C, C=C), 90.6 (N-C-OH), 60.9 (OCH2CH3), 55.9, 55.6 (2 MeO), 20.8, 18.1 (2 Ar-CH₃), 14.4 (OCH₂CH₃). Anal. Calcd for C₃₂H₃₁NO₉ (573 g/mol): C, 67.01; H, 5.45; N, 2.44. Found: C, 66.98; H, 5.40; N, 2.70.

2-[2-(2-Ethoxy-2-oxoethyl)-2-hydroxy-4-(4-methoxybenzoyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]-5methoxybenzoic acid (3m). This compound was obtained as pale yellow crystals, 0.317 g (55%), mp 120 °C, ir (KBr): 3433 (OH, acid), 3256 (OH, alcohol), 1732, 1687, 1627, 1606 (C=O), 1577 cm⁻¹ (C=C); ¹H NMR (300 MHz, DMSO- d_6): δ 7.79–6.72 (m, 11H, Ar–H), 4.08 (q, ³J=7.1, 2H, OCH₂), 3.84, 3.77, 3.68 (3s, 9H, 3 MeO), 2.95 (A part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.61 (B part of AB system, d, 1H, J=15.4, CH₂COOEt), 1.15 (t, ³J=7.1, 3H, Me); ¹³C NMR (75 MHz, DMSO- d_6): δ 193.9, 188.5, 178.6, 168.6 (4 C=O), 163.0, 161.1, 158.8, 136.9, 133.0, 132.3, 132.1, 132.0, 129.2, 128.0, 122.4, 117.9, 115.9, 113.8, 113.6 (Ar–C=C, C=C), 90.4 (N–C–OH), 61.1 (OCH₂CH₃), 56.0, 55.9, 55.6 (3 MeO), 41.5 (C–CH₂COEt), 1.4.4 (OCH₂CH₃). Anal. Calcd for C₃₁H₂₉NO₁₀ (575 g/mol): C, 64.69; H, 5.08; N, 2.43. Found: C, 64.85; H, 5.16; N, 2.82.

2-[2-(2-Ethoxy-2-oxoethyl)-2-hydroxy-4-(4-methoxybenzoyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]-4,5dimethoxybenzoic acid (3n). This compound was obtained as pale yellow crystals, 0.162 g (27%), mp 118 °C, ir (KBr): 3437 (OH, acid), 3258 (OH, alcohol), 1730, 1691, 1636, 1604 (C=O), 1577 cm⁻¹ (C=C); ¹H NMR (300 MHz, CDCl₃): δ 7.77–6.54 (m, 10H, Ar–H), 4.19 (q, ${}^{3}J$ =7.1, 2H, OCH₂), 4.00, 3.84, 3.77, 3.63 (4s, 12H, 4 MeO), 3.35 (A part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.97 (B part of AB system, d, 1H, J=15.4, CH_2COOEt), 1.23 (*t*, ${}^{3}J=7.1$ 3H, Me); ${}^{13}C$ NMR (75 MHz, CDCl₃): δ 194.7, 189.4, 179.2, 169.7 (4C=O), 162.9, 161.4, 152.2, 145.3, 132.0, 131.5, 130.9, 130.2, 128.6, 124.5, 121.3, 113.7, 113.5, 113.1, 112.7 (Ar-C=C, C=C), 91.1 (N-C-OH), 61.4 (OCH₂CH₃), 56.4, 56.1, 55.3, 55.1 (4 MeO), 41.3 (C-CH₂COEt), 14.1 (OCH₂CH₃). Anal. Calcd for C₃₂H₃₁NO₁₁ (605 g/mol): C, 63.47; H, 5.16; N, 2.31. Found: C, 63.20; H, 4.90; N, 2.60.

5-Bromo-2-[2-(2-ethoxy-2-oxoethyl)-2-hydroxy-4-(4methoxybenzoyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1Hpyrrol-1-yl]benzoic acid (30). This compound was obtained as pale yellow crystals, 0.270 g (43%), mp 124 °C, ir (KBr): 3414 (OH, acid), 3232 (OH, alcohol), 1731, 1692, 1631, 1603 (C=O), 1575 cm⁻¹ (C=C); ¹H NMR (300 MHz, DMSO- d_6): δ 7.99–6.75 (m, 11H, Ar–H), 4.08 (q, ³J=7.1, 2H, OCH₂), 3.84, 3.68 (2s, 6H, 2 MeO), 2.98 (A part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.67 (B part of AB system, d, 1H, J=15.4, CH₂COOEt), 1.14 (t, ³J=7.1, 3H, Me); ¹³C NMR (75 MHz, DMSO- d_6): δ 193.9, 188.6, 178.0, 168.6 (4 C=O), 163.1, 161.3, 149.5, 137.4, 135.7, 135.2, 133.8, 132.1, 132.0, 131.4, 122.0, 121.7, 114.0, 113.9, 113.7 (Ar–C=C, C=C), 90.6 (N–C–OH), 61.2 (OCH₂CH₃), 55.9, 55.7 (2 MeO), 41.7 (C–CH₂COEt), 14.3 (OCH₂CH₃). *Anal*. Calcd fo C₃₀H₂₆BrNO9 (624 g/mol): C, 57.70; H, 4.20; N, 2.24. Found: C, 57.76; H, 4.21; N, 2.18.

5-Chloro-2-[2-(2-ethoxy-2-oxoethyl)-2-hydroxy-4-(4-methoxybenzoyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]benzoic acid (3p). This compound was obtained as pale yellow crystals, 0.161 g (28%), mp 101 °C, ir (KBr): 3413 (OH, acid), 3234 (OH, alcohol), 1732, 1692, 1631, 1604 (C=O), 1575 cm⁻¹ (C=C); ¹H NMR (300 MHz, CDCl₃): δ 7.75-6.53 (m, 11H, Ar-H), 4.19 $(q, {}^{3}J = 7.1, 2H, OCH_{2}), 3.76, 3.62$ (2s, 6H, 2 MeO), 3.32 (A part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.92 (B part of AB system, d, 1H, J=15.4, CH_2COOEt), 1.24 (t, ${}^{3}J=7.1$, 3H, Me); ¹³C NMR (75 MHz, CDCl₃): δ 195.1, 189.6, 178.8, 169.1 (4C=O), 132.9, 161.5, 143.8, 135.1, 134.8, 134.5, 132.2, 132.0, 131.7, 131.34, 131.3, 126.4, 120.9, 113.8, 113.1 (Ar-C=C, C=C), 91.1 (N-C-OH), 61.3 (OCH₂CH₃), 55.3, 55.1 (2 MeO), 40.8 (C-CH2COEt), 14.1 (OCH2CH3). Anal. Calcd for C₃₀H₂₆ClNO₉ (580 g/mol): C, 62.13; H, 4.52; N, 2.42. Found: C, 62.40; H, 4.25; N, 2.60.

3-[2-(2-Ethoxy-2-oxoethyl)-2-hydroxy-4-(4-methoxybenzoyl)-5-(4*methoxyphenyl*)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl]propanoic acid This compound was obtained as white crystals, 0.227 g (4a).(46%), mp 152°C; ir (KBr): 3384 (OH, acid), 3178 (OH, alcohol), 1735, 1713, 1692, 1608 (C=O), 1571 cm⁻¹ (C=C); ¹H NMR (300 MHz, DMSO-d₆): δ 12.36 (s, 1H, COOH), 7.66–6.90 (m, 8H, Ar-H), 4.08 (q, ${}^{3}J=7.1$, 2H, OCH₂), 3.81 (2s, 6H, 2 MeO), 3.69-3.47 (m, 2H, CH2N), 3.12 (A part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.93 (B part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.64–2.35 (m, 2H, CH₂CO₂H), 1.16 (t, ³J=7.1, 3H, Me); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 193.7, 187.3, 179.6, 172.4 (4C=O), 162.8, 161.1, 132.2, 131.8, 129.6, 122.5, 114.5, 113.4, 110.6 (Ar-C=C, C=C), 89.0 (N-C-OH), 61.0 (OCH₂CH₃), 55.9, 55.7 (2 MeO), 34.5 (CH₂COOH) 14.4 (OCH₂CH₃). Anal. Calcd for C₂₆H₂₇NO₉ (497 g/mol): C, 62.77; H, 5.47; N, 2.82. Found: C, 62.61; H, 5.40; N, 3.00.

1-[2-Hydroxy-4-(4-methoxybenzoyl)-2-(2-methoxy-2-oxoethyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl] cyclopropanecarboxylic acid (4b). This compound was obtained as white crystals, 0.312 g (63%), mp 137 °C; ir (KBr): 3393, 3154 (OH, alcohol, and acid), 1738, 1698, 1631 cm⁻ (C=O). ¹H NMR (300 MHz, DMSO- d_6): δ 12.66 (b, 1H, OH), 7.80-6.91 (m, 8H, Ar-H), 3.82, 3.78 (2s, 6H, 2 MeO), 3.44 (b, 1H, OH), 3.08 (A part of AB system, d, 1H, J=15.4, CH₂COOMe), 2.99 (B part of AB system, d, 1H, J=15.4, CH_2COOMe), 1.39–0.84 (m, 2× CH_2 , cyclopropane); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 194.4, 187.8, 181.0, 174.0 (4C=O), 163.1, 162.9, 132.2, 132.0, 131.9, 130.1, 123.4, 113.7, 113.5, 111.7 (Ar-C=C, C=C), 89.6 (N-C-OH), 55.9, 55.6, 51.9 (3 MeO), 37.2 (CH₂), 20.5 (CH₂, cyclopropane). Anal. Calcd for C₂₆H₂₅NO₉ (495 g/mol): C, 63.03; H, 5.09; N, 2.83. Found: C, 63.19; H, 5.00; N, 2.86.

1-[2-(2-Ethoxy-2-oxoethyl)-2-hydroxy-4-(4-methoxybenzoyl)-5-(4-methoxyphenyl)-3-oxo-2,3-dihydro-1H-pyrrol-1-yl] *cyclopropanecarboxylic acid* (4*c*). This compound was (m obtained as white crystals, 0.295 g (58%), mp 105 °C; ir (KBr): of 3421 (OH, alcohol, and acid), 1733, 1698, 1633 cm⁻¹ (C=O); AF ¹H NMR (300 MHz, DMSO-*d*₆): δ 12.82 (b, 1H, OH), 7.80–6.91 CI (m, 8H, Ar–H), 4.21–3.99 (m, 2H, OCH₂), 3.82, 3.78 (2s, 6H, 16 2 MeO), 3.38 (b, 1H, OH), 3.06 (A part of AB system, d, 12 1H, *J*=15.4, CH₂COOEt), 2.97 (B part of AB system, d, 14, *J*=15.4, CH₂COOEt), 2.40–2.30, 0.99–0.85 (m, 4H, 60 2× CH₂, cyclopropane), 1.20 (*t*, ³*J*=7.1, 3H, CH₃); ¹³C C, NMR (75 MHz, DMSO-*d*₆): δ 194.4, 187.8, 181.1, 174.0

(4 C=0), 162. 9, 160.6, 132.2, 132.0, 130.0, 123.5, 115.1, 113.7, 113.4, 111.6 (Ar–C=C, C=C), 89.6 (N–C–OH), 60.6 (OCH₂), 55.9, 55.6 (2 MeO), 37.3 (CH₂), 15.4 (Me), 14.4 (CH₂, cyclopropane). *Anal.* Calcd for C₂₇H₂₇NO₉ (509 g/mol): C, 63.65; H, 5.34; N, 2.75. Found: C, 63.56; H, 5.39; N, 2.81.

Methyl [6'-(4-methoxybenzoyl)-5'-(4-methoxyphenyl)-2',7'dioxospiro[cyclobutane-1,3'-pyrrolo[2,1-b][1,3]oxazol]-7a'(7'H)yl]acetate (5a). This compound was obtained as yellow crystals, recrystallized from acetic acid, 0.285 g (58%), mp 91 °C; ir (KBr): 1797, 1744, 1690, 1637 cm⁻¹ (C=O); ¹H NMR (300 MHz, CDCl₃): δ 7.82–6.85 (m, 8H, Ar–H), 3.86, 3.75 (3s, 9H, 3 MeO), 3.13 (A part of AB system, d, 1H, J=15.4, CH₂COOMe), 2.89–1.54 (m, 6H, 3× CH₂, cyclobutane); ¹³C NMR (75 MHz, CDCl₃): δ 191.5, 188.7, 179.2, 175.4 (4 C=O), 163.9, 163.3, 132.1, 130.7, 130.0, 123.3, 120.9, 114.7, 113.6 (Ar–C=C, C=C), 93.9 (N–C–O), 64.5 (N–C–COOH), 55.6, 55.5, 52.3 (3 MeO), 39.6 (CH₂COOMe), 36.3, 30.3, 13.9 (CH₂, cyclobutane). Anal. Calcd for C₂₇H₂₅NO₈ (491 g/mol): C, 65.98; H, 5.13; N, 2.85. Found: C, 65.76; H, 5.29; N, 2.91.

Ethyl [6'-(4-methoxybenzoyl)-5'-(4-methoxyphenyl)-2',7'dioxospiro[cyclobutane-1,3'-pyrrolo[2,1-b][1,3]oxazol]-7a'(7'H)-yl] acetate (5b). This compound was obtained as yellow crystals, recrystallized from acetic acid, 0.320 g (63%), mp 180°C; ir (KBr): 1797, 1739, 1693, 1637 cm^{-1} (C=O); ¹H NMR (300 MHz, CDCl₃): δ 7.84–6.86 (m, 8H, Ar–H), 4.19 (q, ³J=7.1, 2H, OCH₂), 3.87 (2s, 6H, 2 MeO), 3.13 (A part of AB system, d, 1H, J = 15.4, CH₂COOEt), 3.03 (B part of AB system, d, 1H, J = 15.4, CH₂COOEt), 2.89–1.57 (m, 6H, 3× CH₂, cyclobutane), 1.28 $(t, {}^{3}J = 7.1, 3H, Me); {}^{13}C NMR (75 MHz, CDCl_3): \delta 191.4, 188.7,$ 179.3, 175.4 (4C=O), 163.9, 163.3, 132.1, 130.7, 130.1, 123.3, 120.8, 114.7, 113.6 (Ar-C=C, C=C), 94.0 (N-C-O), 64.5 (N-C-COOH), 61.5 (OCH₂), 55.5, 55.4 (2 MeO), 39.8 (CH₂), 36.3, 36.2 (2 CH₂, cyclobutane), 14.1 (Me). Anal. Calcd for C₂₈H₂₇NO₈ (505 g/mol): C, 66.53; H, 5.38; N, 2.77. Found: C, 66.22; H, 5.50; N, 2.52.

General procedure for preparation of pyrrolo[1,2-a][3,1] benzoxazin (6) and 2-methylene pyrrol-3-one (7). Corresponding pyrrol-3-one derivatives (3a,1,n) (1 mmol) and excess of equivalent amount of SOCl₂ (about three to four drops) were stirred at RT in 50 mL benzene for 15 min. Then, the solution was refluxed for 45 min. The solvent was removed by evaporation. The oily residue was subjected to column chromatography on Silica gel 60 HF_{254} . Elution with AcOEt/ hexane (5:1) afforded the product.

Methyl [2-(4-methoxybenzoyl)-1-(4-methoxybenzyl)-3,5-dioxo-5H-pyrrolo[1,2-a][3,1]benzoxazin-3a(3H)-yl]acetate (6a). This compound was obtained as pale yellow crystals, recrystallized from AcOEt, 0.210 g (41%), mp 180 °C; ir (KBr): 1734, 1705, 1645 cm⁻¹ (C=O); ¹H NMR (300 MHz, CDCl₃): δ 8.13–6.46 (m, 12H, Ar–H), 3.86, 3.83, 3.67 (3s, 9H, 3 MeO), 3.48 (A part of AB system, d, 1H, J=15.4, CH₂COOMe), 3.14 (B part of AB system, d, 1H, J=15.4, CH₂COOMe); ¹³C NMR (75 MHz, CDCl₃): δ 189.4, 187.1, 176.5, 167.2 (4 C=O), 163.7, 161.7, 160.4, 136.1, 135.1, 132.1, 131.2, 130.8, 130.4, 130.0, 126.5, 122.6, 119.7, 116.0, 114.1, 113.5 (Ar–C=C, C=C), 88.5 (N–C–O), 55.5, 55.4, 52.3 (3 MeO), 38.3 (CH₂). Anal. Calcd for C₂₉H₂₃NO₈ (513 g/mol): C, 67.83; H, 4.51; N, 2.73. Found: C, 67.80; H, 4.50; N, 2.62.

Ethyl [2-(4-methoxybenzoyl)-1-(4-methoxyphenyl)-7,9-dimethyl-3,5-dioxo-5H-pyrrolo[1,2-a][3,1]benzoxazin-3a(3H)-yl] acetate (61). This compound was obtained as pale yellow crystals, recrystallized from AcOEt, 0.263 g (47%), mp 95 °C; ir (KBr): 1741, 1711, 1645 cm⁻¹ (C=O); ¹H NMR (300 MHz, CDCl₃): δ 7.96–6.78 (m, 10H, Ar–H), 4.14 (q, ³J=7.1, 2H, OCH₂), 3.88, 3.81 (2s, 6H, 2 MeO), 3.50 (A part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.95 (B part of AB system, d, 1H, J=15.4, CH₂COOEt), 2.42, 1.45 (2s, 6H, 2 Ar-CH₃), 1.26 (t, ${}^{3}J$ = 7.1, 3H, Me); 13 C NMR (75 MHz, CDCl₃): δ 189.8, 187.7, 176.7, 167.1 (4 C=O), 163.7, 161.9, 160.9, 138.5, 138.0, 134.1, 132.5, 132.2, 131.0, 130.3, 129.3, 120.8, 120.5, 114.1, 113.9, 113.5 (Ar-C=C, C=C), 89.1 (N-C-O), 61.5 (OCH₂) 55.5, 55.4 (2 MeO), 37.2 (CH₂), 21.0, 17.1 (2 Ar-CH₃), 14.1 (Me). Anal. Calcd for $C_{32}H_{29}NO_8$ (555 g/mol): C, 69.18; H, 5.26; N, 2.52. Found: C, 69.33; H, 5.21; N, 2.71.

Acknowledgments. We wish to dedicate this article to Prof. Dr Yunus Akçamur. The authors are grateful to The Medicinal Plants and Medicine Research Centre of Anadolu University for the use of the X-ray diffractometer. This study was financially supported by The Scientific and Technological Research Council of Turkey (TÜBİTAK), project no. TBAG 107T140.

REFERENCES AND NOTES

[1] Clayden, J.; Read, B.; Hebditch, K. R. Tetrahedron, 2005, 61, 5713.

[2] Betler, B.; Mulle, C. Neuropharmacology 1995, 34, 123.

[3] Schoepp, D.; Smith, C.; Lodge, D.; Millar, J.; Leander, D.; Sacaan, A.; Lunn, W. Eur J Pharmacol 1991, 203, 237.

[4] Dunnil, P. M.; Fowden, L. Phytochemistry, 1965, 4, 933.

[5] Basurto, J. C.; Raya, J. E.; May, M. G.; Fonseca, L. M. E.; Alcantara, I. V.; Ferrara, J. T. J Enzym Inhib Med Ch 2006, 21, 133.

[6] Fan, H.; Peng, J.; Hamann, M. T.; Hu, J. F. Chem Rev 2008, 108, 264; Yasui, E.; Wada, M.; Takamura, N. Tetrahedron Lett, 2009, 50, 4762; Bellina, F.; Rossi, R. Tetrahedron 2006, 62, 7213.

[7] Huang, J. W.; Tan, C. H.; Jiang, S. H.; Zhu, D. Y. Chinese Chem Lett 2004, 15, 305.

[8] Saçmacı, M.; Üngören, Ş. H.; Akçamur, Y.; Arıcı, C.; Ülkü, D. Heteroatom Chem 2005, 16, 235; Saçmacı, M., Üngören, Ş. H., Akçamur, Y. Amino Acids 2006, 31, 397.

[9] Crystallographic data for the structural analysis of compound **5a** has been deposited at the Cambridge Crystallographic Data Centre as deposition no. CCDC 799885. Copies of the data can be obtained, free of charge, on applicant to the Cambridge Crystallographic Data Centre (CCDC), 12 Union Road, Cambridge, CB2 1EZ UK (fax: +44(1223)336033); email:deposit@ccdc@cam. ac.uk

[10] Üngören, Ş. H.; Saçmacı, M.; Akçamur, Y.; Arıcı, C.; Ülkü, D. J Heterocyclic Chem, 2004, 41, 141.

[11] APEX2 and SAINT; Bruker AXS Inc.: Madison, Wisconsin, USA, 2007.

 [12] Sheldrick, G. M. SHELXS 97 Acta Crystallogr. 1990, A46, 467.
[13] Sheldrick, G. M. SHELX97; University of Gottingen: Germany, 1997. [14] Spek, A. L. Platon-A Multipurpose Crystallographic Tool Utrecht; Utrecht University: The Netherlands, 2005.

[15] Macrae, C. F.; Edgington, P. R.; Mc Cabe, P.; Pidcock, E.; Shields, G. P.; Taylor, R.; Towler, M.; Van de Streek, J. J Appl Cryst 2006, 39, 453.

Copyright of Journal of Heterocyclic Chemistry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.